- Healthtech startup Gabify secures $175,000 in pre-seed funding.
- Funds will support clinical validation, tech development, and team growth.
- Gabify aims to impact one million children by 2028 with its AI-powered platform.
Gabify, a promising healthtech startup focused on neurodevelopmental care, has successfully raised $175,000 in a pre-seed funding round led by Inflection Point Ventures. Additionally, the startup has received Rs 25 lakh through the Nidhi Seed Support Scheme from GHRTBI.
The funds will be utilized to enhance clinical validation, further develop the platform’s technology, and expand Gabify’s team. The company has big plans to extend its reach, aiming to impact over one million children by 2028 through various models, including B2B, B2C, and CSR-led initiatives.
Founded in 2023 by Sahil Chopra, Prachi Sood, and Vasyl Leshchuk, Gabify is working on an innovative AI-powered platform designed for the early screening and therapy management of neurodevelopmental disorders like autism and ADHD. The platform combines voice and vision analysis to assess key behavioral indicators and speech patterns, using clinically validated parameters. Gabify also follows a human-in-the-loop approach for clinical validation.
Also Read: InterCosmos Raises Strategic Funding to Advance Space Technology Innovation
The platform has already been tested in over 35 preschools and daycare centers and is currently being used by schools, hospitals, and clinics. Gabify is part of Inflection Point Ventures’ IdeaSchool program and was selected among the top 10 startups under DreamDeal, an initiative by Anupam Mittal.
